2-[(4-amino-butyl)-(2-hydroxy-ethyl)-amino]-ethanol | 54567-20-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[(4-amino-butyl)-(2-hydroxy-ethyl)-amino]-ethanol
• 英文别名: N,N-bis(2-hydroxyethyl)-1,4-butanediamine；N,N-bis-(2-hydroxy-ethyl)-butanediyldiamine；N,N-Bis-(2-hydroxy-aethyl)-butandiyldiamin；2-[4-aminobutyl(2-hydroxyethyl)amino]ethanol
• CAS: 54567-20-3
• 化学式: C₈H₂₀N₂O₂
• 分子量: 176.259
• InChiKey: GSCUXTICYWCTQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  69.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(4-amino-butyl)-(2-hydroxy-ethyl)-amino]-ethanol 在 氯化亚砜 作用下， 生成 N,N-Bis-(2-chlorethyl)-tetramethylendiamin
  参考文献：
  名称：

  Mono- and Difunctional Analogs of Some Quinoline and Acridine Nitrogen Mustards¹

  摘要：

  DOI：

  10.1021/jo01067a094
• 作为产物：
  描述：

  4-[bis-(2-hydroxy-ethyl)-amino]-butyronitrile 在 乙醇 、 镍 作用下， 100.0 ℃ 、11.77 MPa 条件下， 生成 2-[(4-amino-butyl)-(2-hydroxy-ethyl)-amino]-ethanol
  参考文献：
  名称：

  Nitrogen Mustard Analogs of Antimalarial Drugs¹

  摘要：

  DOI：

  10.1021/ja01524a041

文献信息

• Isothiazole derivatives useful as anticancer agents
  申请人：Pfizer Inc.

  公开号：US06235764B1

  公开（公告）日：2001-05-22

  The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.

  本发明涉及式1化合物以及药用可接受的盐、前药和溶剂化物，其中X1，R1，R2和R3按本文定义。本发明还涉及包含上述化合物的药物组合物，以及通过施用上述化合物治疗哺乳动物过度增殖障碍的方法。
• Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds
  申请人：Roche Diagnostics GmbH

  公开号：US20030236266A1

  公开（公告）日：2003-12-25

  The present invention concerns new amino alcohol derivatives, a process for their production as well as pharmaceutical preparations and reagents which contain these substances. The invention concerns pharmaceutical agents of the general formula I 1 in which A denotes hydrogen, a group NR 1 R 2 , a group NR 1 (CH 2 ) p NR 3 R 4 , a group (C═NH)NH 2 or a pyridinyl residue, B and D are the same or different and each denotes a bond, a C 1 to C 6 alkylene residue or a group NR 5 —C 2 to C 6 -alkylene, C denotes piperidinediyl or piperazinediyl, W and X are the same or different and each denotes a bond or a carbonyl group, Y and Z are the same or different and each denotes a saturated or unsaturated hydrocarbon residue with 7 to 24 carbon atoms, R 1 to R 5 are the same or different and each represents hydrogen or a C 1 to C 6 alkyl residue, m is an integer 0, 1 or 2 and if m equals 2 C can also independently of one another be piperidinediyl or piperazinediyl, n and o are the same or different and each denotes the integers 2, 3 or 4 and p denotes an integer from 2 to 6 as well as physiologically tolerated salts thereof, provided that hydrazine derivatives are not included and that m cannot be 0 if A denotes hydrogen or a group (C═NH)NH 2 and B and D being the same or different represent a bond or an alkylene residue.

  本发明涉及新的氨基醇衍生物，其生产方法以及含有这些物质的制药制剂和试剂。该发明涉及通式I1的药用剂，其中A表示氢、基团NR1R2、基团NR1(CH2)pNR3R4、基团(C═NH)NH2或吡啶基,B和D相同或不同，每个表示键、C1到C6烷基残基或基团NR5—C2到C6-烷基,C表示哌啶二基或哌嗪二基,W和X相同或不同，每个表示键或羰基,Y和Z相同或不同，每个表示具有7到24个碳原子的饱和或不饱和碳氢残基，R1到R5相同或不同，每个代表氢或C1到C6烷基残基，m是整数0、1或2，如果m等于2，则C也可以独立地是哌啶二基或哌嗪二基，n和o相同或不同，每个表示整数2、3或4，p表示2到6之间的整数，以及其生理耐受的盐，前提是不包括肼衍生物，并且如果A表示氢或基团(C═NH)NH2，且B和D相同或不同表示键或烷基残基，则m不能为0。
• [EN] ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS<br/>[FR] DERIVES ISOTHIAZOLE UTILES EN TANT QU'AGENTS ANTICANCEREUX
  申请人：PFIZER PRODUCTS INC.

  公开号：WO1999062890A1

  公开（公告）日：1999-12-09

  (EN) The present invention relates to compounds of formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.(FR) La présente invention concerne des composés correspondant à la formule (1), ainsi que des sels, promédicaments et solvates de ces composés, acceptables sur le plan pharmacologique. Dans cette formule, X1, R1, R2 et R3 possèdent les notations données dans la description. L'invention concerne également des compositions pharmaceutiques contenant les composés ci-dessus, ainsi que des méthodes de traitement de troubles hyperproliférants, chez des mammifères, consistant à administrer les composés ci-dessus.

  (中) 本发明涉及公式（1）的化合物和其药学上可接受的盐、前药和溶剂化物，其中X1、R1、R2和R3如本文所定义。本发明还涉及包含上述化合物的制药组合物以及通过给予上述化合物治疗哺乳动物的增殖过度性疾病的方法。
• Isothiazole Derivatives Useful as Anticancer Agents
  申请人：Larson Eric R.

  公开号：US20080300249A1

  公开（公告）日：2008-12-04

  The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X 1 , R 1 , R 2 and R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.

  本发明涉及公式1的化合物及其药学上可接受的盐、前药和溶剂化物，其中X1、R1、R2和R3的定义如本文所述。本发明还涉及包含上述化合物的制药组合物以及通过给予上述化合物治疗哺乳动物的增殖过度性疾病的方法。
• Treating blood or blood products with compounds which have a mustard, aziridinium or aziridine group and a nucleic acid binding group
  申请人：Cerus Corporation

  公开号：US20020182581A1

  公开（公告）日：2002-12-05

  Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.

  本文介绍了处理材料中病原体的方法和组合物，包括在临床实验室处理前净化人体液的方法和在体内使用前净化血液制品的方法。这些技术可处理大量人体血清而不影响检测结果。此外，还考虑了用于生物材料光净化的新型化合物，这些化合物与临床测试兼容，不会干扰血清分析物。